8. Drug-related adverse events.

Adverse events	NPCT (n=129) [n (%)]				PBCT (n=91) [n (%)]
	Grade 1−2	Grade 3	Grade 4		Grade 1−2	Grade 3	Grade 4
ALT, alanine aminotransferase; AST, aspartate aminotransferase; PPE, palmar-plantar erythrodysesthesia; NPCT, non-platinum-based chemotherapy; PBCT, platinum-based chemotherapy; NA, not applicable. No grade 5 adverse events were observed.
Hematological
Leucopenia	38 (29.5)	14 (10.9)	5 (3.9)		24 (26.4)	11 (12.1)	3 (3.3)
Neutropenia	11 (8.5)	13 (10.1)	2 (1.6)		15 (16.5)	6 (6.6)	3 (3.3)
Febrile neutropenia	NA	2 (1.6)	0 (0)		NA	2 (2.2)	0 (0)
Anemia	4 (3.1)	0 (0)	0 (0)		3 (3.3)	4 (4.4)	1 (1.1)
Thrombocytopenia	2 (1.6)	0 (0)	0 (0)		3 (3.3)	5 (5.5)	3 (3.3)
Laboratory-assessed items
Increased ALT/AST	6 (4.7)	0 (0)	0 (0)		9 (9.9)	0 (0)	0 (0)
Increased bilirubin	3 (2.3)	0 (0)	0 (0)		3 (3.3)	0 (0)	0 (0)
Non-hematological
Nausea	16 (12.4)	1 (0.8)	NA		14 (15.4)	0 (0)	NA
Vomiting	9 (7.0)	1 (0.8)	0 (0)		4 (4.4)	1 (1.1)	0 (0)
Anorexic	19 (14.7)	0 (0)	0 (0)		6 (6.6)	0 (0)	0 (0)
Diarrhea	5 (3.9)	0 (0)	0 (0)		4 (4.4)	0 (0)	0 (0)
Abdominal distension	3 (2.3)	0 (0)	NA		5 (5.5)	0 (0)	NA
Constipation	5 (3.9)	0 (0)	0 (0)		3 (3.3)	0 (0)	0 (0)
Fatigue	27 (20.9)	2 (1.6)	NA		13 (14.3)	1 (1.1)	NA
Hyperhidrosis	15 (11.6)	0 (0)	NA		9 (9.9)	0 (0)	NA
Weight loss	3 (2.3)	0 (0)	NA		1 (1.1)	0 (0)	NA
Insomnia	13 (10.1)	1 (0.8)	NA		10 (11.0)	0 (0)	NA
Pain	13 (10.1)	0 (0)	NA		5 (5.5)	0 (0)	NA
Alopecia	17 (13.2)	NA	NA		10 (11.0)	NA	NA
PPE	16 (12.4)	0 (0)	NA		0 (0)	0 (0)	NA
Pruritus	8 (6.2)	0 (0)	NA		4 (4.4)	0 (0)	NA
Hyperpigmentation	7 (5.4)	NA	NA		5 (5.5)	NA	NA
Dyspnea	1 (0.8)	0 (0)	0 (0)		0 (0)	0 (0)	0 (0)
Palpitations	3 (2.3)	NA	NA		0 (0)	NA	NA
Stomatitis	8 (6.2)	0 (0)	0 (0)		2 (2.2)	0 (0)	0 (0)
Peripheral neuropathy	10 (7.8)	1 (0.8)	0 (0)		1 (1.1)	0 (0)	0 (0)
Headache	1 (0.8)	0 (0)	NA		0 (0)	0 (0)	NA
Dizziness	2 (1.6)	0 (0)	NA		1 (1.1)	0 (0)	NA